



FOR IMMEDIATE RELEASE

Dr. Marcel Curlin, MD, Joins Immgenuity's Scientific Advisory Board

Dover, Delaware, August 27, 2023 – Immgenuity, a biotech company focused on developing innovative immunotherapies, announced today that Dr. Marcel Curlin has joined its Scientific Advisory Board.

Dr. Curlin is a renowned expert in the field of HIV and brings over 20 years of experience to Immgenuity's team. He is currently a Professor of Infectious Diseases at Oregon Health and Sciences University (OHSU), where he is engaged in clinical practice and research in HIV.

“We are excited to have Dr. Curlin join our Scientific Advisory Board. Dr. Curlin’s expertise in HIV and his extensive research experience is invaluable in assisting us as we continue to develop our innovative immunotherapies. Dr. Curlin will be providing important guidance and work closely with Immgenuity's team of scientists as we advance our lead compound IMTV014 into the clinic”, said Sateesh Apte, MD, CEO of Immgenuity.

“I am eager to join Immgenuity's Scientific Advisory Board and contribute to the development of new immunotherapies. Immgenuity's innovative approach to HIV Remission has the potential to make a significant impact in the lives of patients, and I look forward to working with the team to bring it to fruition”, said Dr. Curlin.

About Immgenuity, Inc.

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company's lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit <https://immgenuity.com>

About IMTV014

Immgenuity’s immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014 plans to activate the immune system to create a strong, viable immune response against HIV and likely lead to clearing the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as “salvage therapy” in the multidrug resistant population.

Contact: Media Relations: media@immgenuity.com (302) 321-5844

Forward Looking Statements:

This press release contains “forward-looking statements” within the meaning of federal securities law, including statements concerning the company’s outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.